Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, an increase from $31.4 million in 2024, with $1.2 million attributed to the acquisition of IRRAS Holdings, Inc. [10] - Gross margin for 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities increased to $23.9 million in 2025, up from $8.9 million in 2024 [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery Navigation revenue grew to $14.8 million in 2025, including $1.2 million from IRRAflow, primarily due to an expanded installed base and the market release of new products [11] - Capital equipment and software revenue was $3.1 million for 2025, showing a slight decrease compared to previous periods [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - The company is targeting a $1 billion market opportunity across four product segments, expecting double-digit growth in each segment for 2026 [6][21] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate existing markets and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in its existing $1 billion market and generate $200 million in annual revenue [34] Management's Comments on Operating Environment and Future Outlook - Management highlighted the strong financial performance in Q4 2025 and expressed optimism about the future, emphasizing the importance of their biopharma partnerships and clinical trials [21][26] - The management acknowledged challenges related to FDA communications on rare diseases but remains focused on larger patient populations and established markets [40][42] Other Important Information - The company has invested over $100 million in the past five years to build a strong foundation, including a robust pipeline of development programs and an expanded manufacturing footprint [5] - ClearPoint Neuro has over 60 active biopharma partners and is involved in more than 25 active clinical trials [5][24] Q&A Session Summary Question: Clarification on 2026 guidance and organic growth - Management discussed the impact of FDA communications on rare diseases and integration priorities from the IRRAS acquisition on revenue guidance [39][40] - The company expects balanced growth between organic and inorganic sources, with all segments projected to grow in double digits [45][46] Question: Pathway to $200 million revenue - Management indicated a growth rate of 15%-20% could be expected as the company integrates IRRAS and expands its market share [49][50] Question: Updates on expedited review partners - Management confirmed more than 10 partners are in expedited review pathways, with significant indications including Parkinson's disease and drug-resistant epilepsy [60] Question: Timeline for expansion into neuro-oncology - Management emphasized the strength of their commercial team and the importance of upcoming clinical data to support expansion into neuro-oncology [62]

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, an increase from $31.4 million in 2024, with $1.2 million attributed to the acquisition of IRRAS Holdings, Inc. [10] - Gross margin for 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities increased to $23.9 million in 2025, up from $8.9 million in 2024 [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery Navigation revenue grew to $14.8 million in 2025, including $1.2 million from IRRAflow, primarily due to an expanded customer base and the market release of new products [11] - Capital Equipment and Software revenue was $3.1 million for 2025, showing a slight decrease compared to previous periods [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - The company is targeting a $1 billion market opportunity across four product segments, with expectations for double-digit growth in each segment in 2026 [6][21] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate existing markets and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in a combined $1 billion market opportunity, targeting $200 million in annual revenue [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position, highlighting a strong foundation built over the past five years with over $100 million invested [5] - The management noted that the company is well-positioned to support biopharma partners in clinical trials and anticipates significant revenue potential from expedited review programs [25] - Management acknowledged challenges related to FDA communications on rare diseases but emphasized a focus on larger patient populations for growth [40][42] Other Important Information - The company has over 60 active biopharma partners and is involved in more than 25 active clinical trials [5] - ClearPoint Neuro's cash and cash equivalents totaled $45.9 million at the end of 2025, up from $20.1 million in 2024, due to proceeds from notes payable and stock offerings [18] Q&A Session Summary Question: Can you elaborate on the 2026 guidance and the impact of recent FDA communications? - Management indicated that guidance was tightened due to more rigorous FDA requirements for rare diseases and the need to reassess integration priorities with IRRAS [38][40] Question: How should we think about organic growth versus growth from IRRAS? - Management expects balanced growth from both organic and IRRAS contributions, with all segments projected to grow in double digits [45][46] Question: What is the pathway from current revenue to $200 million? - Management anticipates a growth rate of 15%-20% as they capture market share across segments, with potential for significant revenue from large GLP studies [49][50] Question: Can you provide details on new partners in expedited review pathways? - Management confirmed new indications and partners, particularly in Parkinson's disease and drug-resistant epilepsy, enhancing confidence in future revenue [60] Question: What is the timeline for expanding into neuro-oncology with Prism? - Management indicated that the timeline for expansion will depend on the strength of their commercial team and ongoing clinical trials [62]

Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, compared to $31.4 million in 2024, marking an increase of approximately 18% [10] - The gross margin for the full year 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities for 2025 were $23.9 million, an increase of $15 million from 2024, primarily due to a higher net loss and pay down of accounts payable [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery navigation revenue grew to $14.8 million in 2025, including $1.2 million from the IRRAS product line, attributed to an increased installed base and the full market release of new systems [11] - Capital equipment and software revenue was $3.1 million for 2025, showing a slight decrease compared to the previous year [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - ClearPoint is participating in more than 25 active clinical trials and has over 60 active biopharma partners, with more than 10 partner programs accepted for FDA expedited review [5][24] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate a $1 billion market and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in various segments, including pre-commercial biologics and drug delivery, neurosurgery navigation, laser therapy, and neurocritical management [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strong position and momentum going into 2026, highlighting the successful integration of the IRRAS acquisition and the potential for significant revenue growth [21] - The management noted that the FDA's recent communications regarding rare diseases have influenced revenue guidance, leading to a more cautious approach in forecasting [41] Other Important Information - The company has invested over $100 million in the past five years to build a strong foundation, including a robust pipeline of development programs and an expanded manufacturing footprint [5] - ClearPoint's unique biologics and drug delivery ecosystem is expected to play a crucial role in the future of neurological treatments, with a focus on supporting biopharma partners [4][26] Q&A Session Summary Question: Clarification on 2026 guidance and organic growth - Management explained that the guidance was tightened due to FDA communications on rare diseases and the integration of IRRAS, with expectations for balanced organic and inorganic growth [38][46] Question: Pathway to $200 million revenue - Management indicated that they expect to grow at a rate of 15%-20% as they capture market share across their segments, with potential for significant revenue bumps from large GLP studies [48][50] Question: Updates on expedited review partners - Management confirmed that there are over 10 partners in expedited review pathways, with indications including Parkinson's disease and drug-resistant epilepsy, providing higher confidence in potential revenue [60][61] Question: Timeline for expansion in neuro-oncology - Management discussed the strength of their commercial team and the importance of upcoming clinical data to support expansion into neuro-oncology, indicating a serious commitment to this market [62]